Oncology Clinical Trials in Orlando, FL

As of June 2026, 164 paid clinical trials are recruiting for Oncology in Orlando, Florida. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

164 clinical trials for Oncology

·Clear filters·↓ Download CSV

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

for Hematopoietic and Lymphatic System Neoplasm

190 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: Female·Age: Up to 39

Code: NCT06513962·Phase 3·Recruiting

Apply to this trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

for Non-Small Cell Lung Cancer

Drug: Ivonescimab

89 locations incl. Chandler

Sponsor: Summit Therapeutics

Sex: All·Age: 18+

Code: NCT06767514·Phase 3·Recruiting

Apply to this trial

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

for Prostate Cancer

27 locations incl. Los Angeles

Sponsor: Novartis Pharmaceuticals

Sex: Male·Age: 18 - 100

Code: NCT06780670·Phase 2, Phase 3·Recruiting

Apply to this trial

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

for Advanced Solid Tumors

9 locations incl. Orlando

Sponsor: NextCure, Inc.

Sex: All·Age: 18+

Code: NCT06792552·Phase 1·Recruiting

Apply to this trial

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

for Acute Myeloid Leukemia

Drug: Venetoclax

24 locations incl. Los Angeles

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06456463·Phase 2·Recruiting

Apply to this trial

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

for Breast Cancer

17 locations incl. Prescott

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06695845·Phase 2·Recruiting

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

Drug: Amivantamab

150 locations incl. Daphne

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting

Apply to this trial

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma

8 locations incl. Duarte

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06628310·Phase 2·Recruiting

Apply to this trial

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

for Colorectal Neoplasms

Drug: Amivantamab

70 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06750094·Phase 3·Recruiting

Apply to this trial

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

for Neuroblastoma

12 locations incl. Little Rock

Sponsor: Giselle Sholler

Sex: All·Age: 1 - 21

Code: NCT06540963·Phase 2·Recruiting

Apply to this trial

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

16 locations incl. Farmington

Sponsor: Johnson & Johnson Enterprise Innovation Inc.

Sex: All·Age: 18+

Code: NCT06667908·Phase 2·Recruiting

Apply to this trial

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

for Solid Tumor

20 locations incl. Birmingham

Sponsor: Corbus Pharmaceuticals Inc.

Sex: All·Age: 18+

Code: NCT06603844·Phase 1, Phase 2·Recruiting

Apply to this trial

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

for Neuroblastoma

20 locations incl. Birmingham

Sponsor: Milton S. Hershey Medical Center

Sex: All·Age: Up to 30

Code: NCT06541262·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

for Endometrial Cancer

Drug: Lifileucel

12 locations incl. Phoenix

Sponsor: Iovance Biotherapeutics, Inc.

Sex: Female·Age: 18 - 70

Code: NCT06481592·Phase 2·Recruiting

Apply to this trial

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

for Advanced Breast Cancer

35 locations incl. Springdale

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06638307·Phase 1·Recruiting

Apply to this trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

for Advanced Cancer

4 locations incl. Denver

Sponsor: Shanghai Allink Biotherapeutics Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT06656390·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

for Colorectal Neoplasms

Drug: Amivantamab

79 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06662786·Phase 3·Recruiting

Apply to this trial

A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

for Hematopoietic and Lymphatic System Neoplasm

76 locations incl. Mesa

Sponsor: Children's Oncology Group

Sex: All·Age: 15 - 20

Code: NCT06410209·Phase 2·Recruiting

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

165 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting

Apply to this trial

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

for Head and Neck Squamous Cell Carcinoma

Drug: Petosemtamab

37 locations incl. Mobile

Sponsor: Merus B.V.

Sex: All·Age: 18+

Code: NCT06525220·Phase 3·Recruiting

Apply to this trial

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

for Solid Tumor

19 locations incl. Little Rock

Sponsor: NiKang Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06586957·Phase 1·Recruiting

Apply to this trial

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

for Pancreatic Ductal Adenocarcinoma

25 locations incl. Duarte

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06586515·Phase 1·Recruiting

Apply to this trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

for Advanced Breast Cancer

Drug: Camizestrant

54 locations incl. Gilbert

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06380751·Phase 3·Recruiting

Apply to this trial

Investigations of Reproductive Cancers in Women

for Uterine Cancer

16 locations incl. Birmingham

Sponsor: PinkDx, Inc.

Sex: Female·Age: 45 - 100

Code: NCT06527157·Recruiting

Apply to this trial

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

for Biliary Tract Cancer

21 locations incl. Duarte

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06282575·Phase 3·Recruiting

Apply to this trial

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

for Hepatocellular Carcinoma

Drug: Atezolizumab

60 locations incl. Tucson

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT06096779·Phase 2·Recruiting

Apply to this trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

for Solid Tumors

18 locations incl. Birmingham

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT06431594·Phase 1·Recruiting

Apply to this trial

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

for Rectal Cancer

101 locations incl. Phoenix

Sponsor: Canadian Cancer Trials Group

Sex: All·Age: 18+

Code: NCT06205485·Phase 3·Recruiting

Apply to this trial

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

for Head and Neck Squamous Cell Carcinoma

Drug: Petosemtamab

61 locations incl. Mobile

Sponsor: Merus B.V.

Sex: All·Age: 18+

Code: NCT06496178·Phase 3·Recruiting

Apply to this trial

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for Large B-cell Lymphoma

60 locations incl. Gilbert

Sponsor: Allogene Therapeutics

Sex: All·Age: 18+

Code: NCT06500273·Phase 2·Recruiting

Apply to this trial

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

Drug: Ruxolitinib

58 locations incl. Birmingham

Sponsor: Kartos Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06479135·Phase 3·Recruiting

Apply to this trial

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

for Solid Tumor, Adult

10 locations incl. Denver

Sponsor: Kumquat Biosciences Inc.

Sex: All·Age: 18+

Code: NCT06507306·Phase 1·Recruiting

Apply to this trial

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

for Small Cell Lung Cancer

30 locations incl. Springdale

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06203210·Phase 3·Recruiting

Apply to this trial

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

for Acute Myeloid Leukemia

Drug: Venetoclax

7 locations incl. Miami

Sponsor: Joshua Zeidner

Sex: All·Age: 18+

Code: NCT05442216·Phase 2·Recruiting

Apply to this trial

A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

for Advanced Solid Tumors

11 locations incl. Aurora

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Sex: All·Age: 18+

Code: NCT06384352·Phase 1·Recruiting

Apply to this trial

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

for Solid Tumor

17 locations incl. Duarte

Sponsor: Biohaven Therapeutics Ltd.

Sex: All·Age: 18+

Code: NCT06384807·Phase 1, Phase 2·Recruiting

Apply to this trial

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

for Ganglioneuroblastoma, Nodular

156 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 30

Code: NCT06172296·Phase 3·Recruiting

Apply to this trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for Breast Neoplasms

46 locations incl. Chandler

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312176·Phase 3·Recruiting

Apply to this trial

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

5 locations incl. Los Angeles

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06233942·Phase 1·Recruiting

Apply to this trial

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

for Non-Small Cell Lung Cancer

Drug: Rilvegostomig

63 locations incl. Anchorage

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06357533·Phase 3·Recruiting

Apply to this trial

Conditions in Oncology (Orlando, FL)

Solid tumor· 34 Non-small cell lung cancer (NSCLC)· 26 Breast cancer· 18 Ovarian cancer· 15 Cancer (any)· 14 Endometrial cancer· 13 Colorectal cancer· 12 Pancreatic cancer· 10 Neuroblastoma· 9 Esophageal cancer· 8 Cervical cancer· 8 Head and neck cancer· 8 Triple-negative breast cancer· 7 Lung cancer· 7 Gastric cancer· 7 Prostate cancer· 7 Non-Hodgkin lymphoma· 7 Metastatic breast cancer· 6 Gastroesophageal junction cancer· 6 Acute myeloid leukemia (AML)· 6 HER2-negative breast cancer· 5 Bladder cancer· 5 Small cell lung cancer· 4 Metastatic prostate cancer· 4 Fallopian tube cancer· 4 Hematologic malignancy· 4 Melanoma· 4 Osteosarcoma· 4 Biliary tract cancer· 3 Multiple myeloma· 3 Liver cancer· 2 Leukemia (other)· 2 Myelodysplastic syndromes (MDS)· 2 Hodgkin lymphoma· 2 Diffuse large B-cell lymphoma (DLBCL)· 2 Ewing sarcoma· 2 Mesothelioma· 2 HER2-positive breast cancer· 1 Metastatic colorectal cancer· 1 Rectal cancer· 1 Gastrointestinal cancer· 1 Kidney cancer· 1 Uterine cancer· 1 Gynecologic cancer· 1 Glioma· 1 Brain cancer· 1 Acute lymphoblastic leukemia· 1 Myelofibrosis· 1 Myeloproliferative neoplasm· 1 Follicular lymphoma· 1 Marginal zone lymphoma· 1 Burkitt lymphoma· 1 Rhabdomyosarcoma· 1 Pediatric cancer· 1